🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Triple -Negative Breast Cancer

Access to Genetic Testing in Underserved Patients With Cancer NCT06422455NA2 sites📍 Los Angeles📍 Rochester University of Southern California · Tests: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) NCT07743190Phase 22 sites📍 Syracuse📍 Charleston Medical University of South Carolina · Tests: Carboplatin, Paclitaxcel, Pembrolizumab PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC NCT06245889Phase 22 sites📍 Baltimore📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide Viscum Album for TNBC on Adjuvant Pembrolizumab NCT06920810Phase 41 site📍 Goyang-si Ilsan Cha hospital · Tests: viscum album Pucotenlimab and Anlotinib in Combination With Chemotherapy NCT07896668Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: LP Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer NCT06631092Phase 1, Phase 22 sites📍 Erlangen📍 Heidelberg NEC Bio B.V · Tests: Oral DNA Vaccine Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy NCT07311083NA1 site📍 Essen Kliniken Essen-Mitte · Tests: switching to a high-fibre diet, official dietary recommendations I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer NCT06938724Phase 21 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Omission of local therapies A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. NCT07340424EARLY Phase 11 site📍 Jinan Xiaorong Sun · Tests: 225Ac-TR2205 Injection Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery NCT05973864Phase 220 sites📍 Amiens📍 Avignon📍 Bayonne UNICANCER · Tests: Pembrolizumab injection, Capecitabine tablets, Local radiotherapy Phase 1 Study of CLR 125 in Triple Negative Breast Cancer NCT07311993Phase 14 sites📍 Jacksonville📍 Glen Burnie📍 Rochester Cellectar Biosciences, Inc. · Tests: Iopofosine I 131, CLR 125 Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer NCT07401537Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Extended-Dose Interval Immunotherapy, Standard-Dose Interval Immunotherapy Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer NCT05550415Phase 21 site📍 Jakarta Pusat Universitas Indonesia · Tests: Simvastatin 40mg, Placebo Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer NCT04138719Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Epirubicin Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients NCT06273800NA1 site📍 Amsterdam The Netherlands Cancer Institute · Tests: Blood sample Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer NCT06606730Phase 32 sites📍 Brussels📍 Villejuif UNICANCER · Tests: Pembrolizumab, Deescalation First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. NCT07299409Phase 21 site📍 Vancouver Nathalie Levasseur · Tests: Sacituzumab Govitecan (SG) TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer NCT06931769n/a9 sites📍 Enschede📍 Amsterdam📍 Amsterdam The Netherlands Cancer Institute AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527Phase 31 site📍 Beijing Akeso · Tests: AK112, Nab-paclitaxel, Placebo A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors NCT06700070EARLY Phase 11 site📍 Shreveport Pure Biologics S.A. · Tests: PBA-0111 Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer NCT07276880Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer NCT03740893Phase 26 sites📍 Bournemouth📍 London📍 Manchester Institute of Cancer Research, United Kingdom · Tests: AZD6738, Olaparib, Durvalumab A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413 Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) NCT05722795NA1 site📍 Gothenburg Vastra Gotaland Region · Tests: Imatinib 400 MG Oral Tablet A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer NCT06878625Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients NCT06690840Phase 25 sites📍 Monza📍 Roma📍 Roma European Institute of Oncology · Tests: Atezolizumab in combination with Cyclophosphamide and Vinorelbine Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy